CARDIOPROGRESS
Foundation for the advancement of cardiology

Biologic Drugs May Mitigate Cardiovascular Event Risks in Patients With Rheumatoid Arthritis Patients with heart defects are at risk of developing cardiovascular disease. Our objective was to determine if non-cardiac birth defects are associated with the risk of cardiovascular hospitalisation.

Urate in Atherosclerotic Plaques Boosts Risk for CV Events Patients with gout and hyperuricemia harboring cardiovascular (CV) monosodium urate (MSU) deposits in atherosclerotic plaques are at an increased risk for major adverse cardiovascular events (MACE).

Don't Overlook Underlying CV Risks In RA Treatmen Patients with rheumatoid arthritis (RA) carry a high risk for cardiovascular events, but mounting clinical evidence suggests they're being undertreated to manage that risk. Rheumatologists should consider a patient with RA's cardiovascular disease (CVD) status before deciding on RA treatments, a researcher of cardiometabolic disorders advised.

Microvascular disease and arrhythmias: a renewed focus on the myocardial microvasculature? Arrhythmias, and in particular atrial fibrillation (AF), are one of the greatest healthcare challenges of our time. Hospitalisation due to this condition is exponentially growing, and now outnumbers those for both heart failure and myocardial infarction.

In Angina, Gene Therapy Coaxes Heart Vessel Growth An experimental new gene therapy has specialists questioning whether heart vessel growth to restore blood flow could actually be possible in refractory angina after bypass surgery.

Prenatal Exercise Cuts Common Pregnancy Complications Moderate-intensity physical activity during pregnancy is known to be safe for the mother and foetus, but does it reduce the risk for medical complications? A new up-to-date review summarises the data, including seven meta-analyses, which establishes that prenatal exercise prevents hypertension disorders in pregnancy (HDP), including gestational diabetes mellitus (GDM). These are the most common medical complications of pregnancy, affecting up to 15% of pregnant women.

Heart Failure, Not Stroke, Most Common Complication of A-Fib The lifetime risk of atrial fibrillation (AF) increased from 2000 to 2022 from one in four to one in three, a Danish population-based study of temporal trends found.

Incremental value of machine learning for risk prediction in tetralogy of Fallot Machine learning (ML) can facilitate prediction of major adverse cardiovascular events (MACEs) in repaired tetralogy of Fallot (rTOF). We sought to determine the incremental value of ML above expert clinical judgement for risk prediction in rTOF.

Can Treating Depression Mitigate CVD Risk? Depression is linked to a significantly increased risk for cardiovascular disease (CVD), particularly in women, new data from a large retrospective cohort study show. Researchers suggest that screening and treating patients for depression may lead to a decreased incidence of CVD.

Gout Increases the Risk for a Wide Range of Cardiovascular Diseases People with gout are 58% more likely to develop cardiovascular disease (CVD), according to a new analysis. This increased risk was observed across 12 different cardiovascular conditions, including heart failure, arrhythmias, and valve diseases.

EASD to Feature Major Trial Results, Clinical Guidance The European Association for the Study of Diabetes (EASD) 2025 Annual Meeting will feature major clinical trial results in type 2 diabetes (T2D), type 1 diabetes (T1D), obesity, several new clinical practice guidelines, and much more.

2025 ESC Congress HOT LINE sessions: key clinical studies From August 29 to September 1, 2025, the regular Congress of the European Society of Cardiology was held in Madrid (Spain), combined this year with the World Congress of Cardiology. The main theme of the event was "Global Health: Cardiology Without Borders".
This event brought together leading experts and researchers from different countries and allowed them to discuss new research and achievements in the treatment of cardiovascular diseases.

Mortality Still Significant in High-Risk PE Despite Advances 1 in 5 patients with high-risk pulmonary embolism (PE) and more than 2 in 5 with catastrophic PE with hemodynamic collapse die in the hospital, a large contemporary analysis showed.

ECG Deep-Learning Algorithm Predicts Mortality Post Surgery Algorithm interpreting preoperative ECGs can identify risk for postoperative death in those undergoing cardiac surgery, noncardiac surgery, and interventional procedures, a large new study showed. The algorithm was more effective in identifying high-risk patients who went on to experience postoperative mortality than a widely used risk tool.

FDA Approves First Pulsed Field Ablation System for AF The US Food and Drug Administration (FDA) has approved the PulseSelect Pulsed Field Ablation (PFA) System (Medtronic) for the treatment of both paroxysmal and persistent atrial fibrillation (AF), the manufacturer has announced.

A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic Syndrome A growing appreciation of the pathophysiological interrelatedness of metabolic risk factors such as obesity and diabetes, chronic kidney disease, and cardiovascular disease has led to the conceptualization of cardiovascular-kidney-metabolic syndrome. The confluence of metabolic risk factors and chronic kidney disease within cardiovascular-kidney-metabolic syndrome is strongly linked to risk for adverse cardiovascular and kidney outcomes.

In memory of Umida Kabirovna Kamilova November 21, 2023. Passed away at the age of 61. Professor Umida Kabirovna Kamilova, Doctor of Medical Sciences. She devoted her life and work to medicine.

ACC/AHA Issue Updated Atrial Fibrillation Guideline The American College of Cardiology (ACC), the American Heart Association (AHA), the American College of Chest Physicians (ACCP), and the Heart Rhythm Society (HRS) have issued an updated guideline for preventing and optimally managing atrial fibrillation (AF).

One step closer to the new frontiers of healthcare for cardiomyopathy patients There were great advances in the treatment of heart failure (HF) over the past decades, characterised by the inclusion of ARNI and SGLT2 inhibitors in the latest guidelines. The use of cardiac myosin inhibitors specifically for patients with hypertrophic cardiomyopathy (HCM) is also making large steps forward, which reflects the next step towards more personalised treatment.

Roles for cardiologists in government, research councils and regulatory sectors Clinicians have numerous opportunities to gain experience in governmental or regulatory organisations, including health technology assessment bodies and payors. These organisations often seek advice from individuals with clinical experience and knowledge, and they increasingly engage with the clinical community on a regular basis. Cardiologists can also take on formal advisory roles, either through working groups or ad hoc and standing committees. Additionally, there may be part-time or full-time employment opportunities available, often providing leadership in research councils.